Anbio Biotechnology 20-F annual reports
The annual report filed by foreign private issuers listed on a US exchange — the 10-K’s equivalent for non-US companies.
NASDAQ
Anbio Biotechnology files an amendment to its 2025 annual report on Form 20-F, primarily to update its status as a well-known seasoned issuer.
NASDAQ
Anbio Biotechnology's 2025 annual report shows significant revenue growth and improved profitability, driven by a diversified product portfolio and strategic market expansion.
NASDAQ
20-F: Anbio Biotechnology Reports Fiscal Year 2024 Results, Highlights Growth and Strategic Initiatives
Anbio Biotechnology's 20-F filing reveals a year of revenue growth, strategic market expansion, and ongoing efforts to navigate regulatory landscapes and diversify its IVD product portfolio.